Protalix Biotherapeutics Inc (PLX)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $255.49M
Last updated: Nov 17, 2026 at 4:30 PM ET
Protalix Biotherapeutics Inc (PLX) Stock Chart
Protalix Biotherapeutics (PLX) has a latest price of $2.90 on Nov 17, 2026, 9.2% below its 52-week high of $3.19. Its price rose 55.6% over the past 12 months. The month-end price fell 44.9% over the 10 years through Oct 2026, a compound annual decline of 5.8%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $13.60 in Mar 2017 and its lowest $0.83 in Dec 2021, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart PLX with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for PLX.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 23.2%, and over 6 months it rose 52.4%. The month-end price rose 55.1% over the 3 years through Oct 2026, a compound annual rate of 15.8%.
| Period | Change |
|---|---|
| 1 month | +13.1% |
| 3 months | +23.2% |
| 6 months | +52.4% |
| 12 months | +55.6% |
| 12 months, with dividends | +55.6% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +55.1% | +15.8% |
| 5 years | +129.2% | +18.0% |
| 10 years | -44.9% | -5.8% |
Price by Year
Its best calendar year was 2022, when the price rose 64.7%, and its weakest was 2021, when it fell 77.1%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $2.59 | +43.9% |
| 2025 | $1.80 | -4.3% |
| 2024 | $1.88 | +5.6% |
| 2023 | $1.78 | +29.9% |
| 2022 | $1.37 | +64.7% |
| 2021 | $0.83 | -77.1% |
| 2020 | $3.63 | +10.7% |
| 2019 | $3.28 | +5.5% |
| 2018 | $3.11 | -53.0% |
| 2017 | $6.61 | +48.6% |
Trading Range
The price is 7.1% above its 50-day average of $2.70 and 18.0% above its 200-day average of $2.45.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $2.90 | |
| 52-week high | $3.19 | -9.2% |
| 52-week low | $1.65 | +75.5% |
| 50-day average | $2.70 | +7.1% |
| 200-day average | $2.45 | +18.0% |
Price Risk
Over 3 years, its largest fall from a peak was 56.0%.
| Measure | Value |
|---|---|
| 1-year beta | 1.06 |
| Largest fall, 1 year | -39.7% |
| Largest fall, 3 years | -56.0% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About PLX
What is PLX's 1-year price change?
Protalix Biotherapeutics's price rose 55.6% over the past 12 months. With dividends included, the 12-month total return was 55.6%.
What is PLX's 5-year price change?
Protalix Biotherapeutics's month-end price rose 129.2% over the 5 years through Oct 2026, a compound annual rate of 18.0%. These figures leave out dividends.
What is PLX's 52-week high and low?
Protalix Biotherapeutics's 52-week high is $3.19 and its 52-week low is $1.65. Its latest price of $2.90 on Nov 17, 2026 is 9.2% below the high.
What is PLX's beta?
Protalix Biotherapeutics's 1-year beta against the S&P 500 is 1.06, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 39.7%.
Is the PLX chart free?
Yes. Advanced Charting for PLX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
PLX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors